News | October 13, 2021
PCI Pharma Services acquires LSNE for its CDMO business
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
